Who is the manufacturer of Tevimbra (Tislelizumab-jsgr)?

Tevimbra (Tislelizumab-jsgr) is an anti-programmed death receptor 1 (PD-1) monoclonal immunoglobulin G 4 antibody developed by Chinese biopharmaceutical company BeiGene. As an innovative immunotherapy drug, Tevimbra is designed to maximize the inhibition of PD-1 binding to programmed death ligand 1 (PD-L1) while reducing its binding to Fcγ receptors. This structural optimization enables Tevimbra to show stronger specificity and better anti-tumor effect in clinical applications.

In clinical studies,Tevimbra has shown preliminary anti-tumor effects in a variety of solid tumors, including but not limited to Hodgkin lymphoma, urothelial cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, liver cancer, nasopharyngeal cancer, and colorectal cancer. It is worth noting that when Tevimbra is combined with other drugs such as ociperlimab, it further broadens its application potential in the treatment of solid tumors.

Due to its remarkable results in anti-tumor effects,Tevimbra has been approved by the National Medical Products Administration and has become an important treatment option for the treatment of classic Hodgkin lymphoma, urothelial carcinoma, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer and hepatocellular carcinoma. In addition, its new indications in microsatellite instability-high/mismatch repair-deficient tumors are also being actively studied. The U.S. Food and Drug Administration (FDA) has also granted Tevimbra orphan drug status, which is suitable for the treatment of hepatocellular carcinoma, esophageal cancer, and gastric cancer (including gastroesophageal junction cancer). This undoubtedly provides a broad market space for the international development of this drug.

Tevimbra had an acceptable safety profile; the most common side effects included fatigue, anemia, and decreased neutrophil count, while the most fatal events were associated with respiratory infection or failure and liver damage. Tevimbra has economic advantages compared with other well-studied PD-1/PD-L1 inhibitors; therefore, its introduction could provide clinical oncologists with an effective anti-tumor weapon and potentially reduce the burden on cancer patients.

Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC9358212/